NAD supplements for nerve health in glaucoma
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether NAD precursor supplements can improve nerve health and vision in people with glaucoma. If you have glaucoma with mild to moderate vision loss, this study may help understand if these supplements could protect your optic nerve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a diagnosis of glaucoma
- Be 18 years or older
- Have corrected vision of at least 20/40 in the better eye
- Have eye pressure under 21 mmHg (controlled)
- Have mild to moderate vision loss from glaucoma (better than -24 dB on a visual field test)
- Not have other eye diseases (like diabetic retinopathy, severe nearsightedness, or infections) that could affect vision
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether metformin can slow damage to the optic nerve in people with glaucoma. It uses eye scans and vision tests to look for changes over time, aiming to help preserve sight.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
This study measures levels of nicotinamide (a form of vitamin B3) in different eye fluids of people with glaucoma and compares them to people without glaucoma. It aims to understand how nicotinamide relates to cell damage and aging in the eye, which could help develop new treatments.
This trial tests whether a dietary supplement (DHA + citicoline) can help protect vision in people with glaucoma. You may qualify if you have confirmed glaucoma in at least one eye and are between 50 and 75 years old.
This study looks at whether a common class of glaucoma eye drops (called prostaglandin analogues) can protect the nerve cells in the back of the eye. It may help people with certain types of glaucoma who have been stable on one type of eye drop for at least 3 years.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.